0001179110-19-001330.txt : 20190205 0001179110-19-001330.hdr.sgml : 20190205 20190205163223 ACCESSION NUMBER: 0001179110-19-001330 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190201 FILED AS OF DATE: 20190205 DATE AS OF CHANGE: 20190205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schwartz Carl I. CENTRAL INDEX KEY: 0001573354 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36790 FILM NUMBER: 19568372 MAIL ADDRESS: STREET 1: 20155 N.E. 38TH COURT, UNIT 3104 CITY: AVENTURA STATE: FL ZIP: 33180 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Precision Therapeutics Inc. CENTRAL INDEX KEY: 0001446159 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 331007393 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2915 COMMERS DRIVE, STREET 2: SUITE 900 CITY: EAGAN STATE: MN ZIP: 55121 BUSINESS PHONE: 651-389-4800 MAIL ADDRESS: STREET 1: 2915 COMMERS DRIVE, STREET 2: SUITE 900 CITY: EAGAN STATE: MN ZIP: 55121 FORMER COMPANY: FORMER CONFORMED NAME: Precision Therapeutic Inc. DATE OF NAME CHANGE: 20180208 FORMER COMPANY: FORMER CONFORMED NAME: Skyline Medical Inc. DATE OF NAME CHANGE: 20130807 FORMER COMPANY: FORMER CONFORMED NAME: BioDrain Medical, Inc. DATE OF NAME CHANGE: 20080925 4 1 edgar.xml FORM 4 - X0306 4 2019-02-01 0 0001446159 Precision Therapeutics Inc. AIPT 0001573354 Schwartz Carl I. 3750 LAS VEGAS BLVD. SOUTH APT. 4303 LAS VEGAS NV 89158 1 1 0 0 Chief Executive Officer Common Stock 144298 D Amended and Restated Warrant to purchase common stock 0.704 2019-02-01 4 J 0 6227 A 2019-07-08 2024-01-08 Common Stock 6227 969707 D This Amended and Restated Warrant (the "Warrant") amends and restates that certain warrant issued on November 30, 2018 (the "Original Warrant"), due to a second investment of an additional $950,000, resulting in a total investment of $1,320,000. (See Form 4 filed on December 10, 2018 for details of the Original Warrant.) In addition to the shares reported, the Warrant provides for additional shares to be added to the Warrant beginning on February 1, 2019 and the first day of each calendar month thereafter, equal to (1) one-half percent (1/2%) of the outstanding principal balance of the Note on such date, divided by (2) the closing price of Common Stock on that date. The number of warrant shares is subject to a share limit such that the total of number of warrant shares issued under the Warrant, together with the 78,125 shares purchased directly, may not exceed 2,818,350 shares. Additional shares added to the Warrant as of 2/1/2019. /s/ Carl I. Schwartz, DDS 2019-02-05